Vigabatrin: What Went Wrong with the Anti-Epileptic Wonder Drug?

As vigabatrin was being used, it became associated with retinal toxicity causing constriction of the visual field. These visual field deficits reported in association with vigabatrin prompted a review of its place in the management of epilepsy, halting its use. However, in 2009, it was later approved by the United States Food and Drug Administration (FDA) for use as monotherapy in the treatment of infantile spasms in patients aged 1 month to 2 years, based on the benefits of the treatment outweighing the risks.